Methods for treating inflammation-mediated conditions of the eye
First Claim
Patent Images
1. A method for treating an inflammation-mediated condition of the eye in an individual, comprising:
- implanting into the vitreous of the eye a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.05 μ
g/ml dexamethasone within about 48 hours and maintains a concentration equivalent to at least about 0.03 μ
g/ml dexamethasone for at least about three weeks.
1 Assignment
0 Petitions
Accused Products
Abstract
Methods for treating inflammation-mediated conditions of the eye are described, comprising: implanting into the vitreous of the eye of an individual a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.05 μg/ml dexamethasone within about 48 hours and maintains a concentration equivalent to at least about 0.03 μg/ml dexamethasone for at least about three weeks.
45 Citations
34 Claims
-
1. A method for treating an inflammation-mediated condition of the eye in an individual, comprising:
- implanting into the vitreous of the eye a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.05 μ
g/ml dexamethasone within about 48 hours and maintains a concentration equivalent to at least about 0.03 μ
g/ml dexamethasone for at least about three weeks. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)
- implanting into the vitreous of the eye a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.05 μ
-
15. A method for treating an inflammation-mediated condition of the eye in an individual, comprising:
- implanting a solid body into the vitreous of the eye, said body comprising particles of a steroidal anti-inflammatory agent entrapped within a bioerodible polymer, whereby said agent is released from the body by erosion of the polymer, and whereby said agent is delivered to the vitreous at a rate and for a time sufficient to reach a concentration equivalent to at least about 0.05 μ
g/ml dexamethasone within about 48 hours, and maintains a concentration equivalent to at least about 0.03 μ
g/ml dexamethasone for at least about three weeks.
- implanting a solid body into the vitreous of the eye, said body comprising particles of a steroidal anti-inflammatory agent entrapped within a bioerodible polymer, whereby said agent is released from the body by erosion of the polymer, and whereby said agent is delivered to the vitreous at a rate and for a time sufficient to reach a concentration equivalent to at least about 0.05 μ
-
16. A method for treating an inflammation-mediated condition of the eye in an individual, comprising:
- implanting into the vitreous of the eye a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.2 μ
g/ml dexamethasone within about 6 hours and maintains a concentration equivalent to at least about 0.01 μ
g/ml dexamethasone for at least about three weeks. - View Dependent Claims (17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)
- implanting into the vitreous of the eye a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.2 μ
-
32. A method for treating an inflammation-mediated condition of the eye in an individual, comprising:
- implanting a solid body into the vitreous of the eye, said body comprising particles of a steroidal anti-inflammatory agent entrapped within a bioerodible polymer, whereby said agent is released from the body by erosion of the polymer, and whereby said agent is delivered to the vitreous at a rate and for a time sufficient to reach a concentration equivalent to at least about 0.2 μ
g/ml dexamethasone within about 6 hours, and maintains a concentration equivalent to at least about 0.01 μ
g/ml dexamethasone for at least about three weeks.
- implanting a solid body into the vitreous of the eye, said body comprising particles of a steroidal anti-inflammatory agent entrapped within a bioerodible polymer, whereby said agent is released from the body by erosion of the polymer, and whereby said agent is delivered to the vitreous at a rate and for a time sufficient to reach a concentration equivalent to at least about 0.2 μ
-
33. A solid bioerodible implant for treating an inflammation-mediated condition of the eye, consisting essentially of:
- dexamethasone particles entrapped within a polylactic acid polyglycolic acid (PLGA) copolymer, wherein the implant comprises about 70 percent by weight of dexamethasone and about 30 percent by weight of PLGA, wherein the total mass of the implant is about 800-1100 μ
g, and wherein the implant releases at least about 10% of the drug load within 1 week when measured under infinite sink conditions in vitro.
- dexamethasone particles entrapped within a polylactic acid polyglycolic acid (PLGA) copolymer, wherein the implant comprises about 70 percent by weight of dexamethasone and about 30 percent by weight of PLGA, wherein the total mass of the implant is about 800-1100 μ
-
34. A kit for treating an inflammation-mediated condition of the eye in an individual comprising:
-
a) a container comprising a bioerodible implant comprising dexamethasone and polylactic acid polyglycolic acid (PLGA) copolymer in a ratio of about 70/30; and
b) instructions for use.
-
Specification